| |
|
|
|
Xtalks, Online
2024-05-28
As the frontiers of multi-disciplined scientific arena, cell and gene therapy (CGT) is unlocking its potential in treating those incurable illness, thus changing the life of patients. While fueled with momentum of investment opportunities, challenges in clinical operations and market access are posed in front of Asia Pacific region located biotech companies.
In this webinar, the attendees will get an in-depth understanding of the opportunities of CGT product development and market entry strategies in this fast-evolving industry. Attendees will investigate the prospectus of operational excellence, investigator engagement as well as patient recruitment on accelerating the journey, while explore Fortrea’s solution in navigating the complexity of clinical studies in CGT and share the best practices in supporting the success of both emerging biotech and large pharmaceutical sponsors.
In addition to the online presentations, feel free to book a seat in actual site of Seoul, Korea or Singapore to join face to face discussion with Fortrea experts as well as key stakeholders covering CGT ecosystem. Share the insights from various facets on advancing CGT clinical development in Asia Pacific.
Register for this webinar today to understand the opportunities of the CGT trial ecosystem and market entry strategies for biotech companies located in the Asia-Pacific region. Participants can also book a seat to attend on-site in Seoul, Korea or Singapore on May 28 to see the live presentation and meet with Fortrea experts (information will be provided upon registering for the webinar).
Keywords: Drug Development, Clinical Research, Regulatory, Clinical Trials in Asia, APAC, Asia-Pacific, Cell & Gene Therapies, Commercialization/HEOR/Market Access, CT Logistics
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Frederick Derosier, Vice President, Therapeutic Strategy, Clinical Lead for Enterprise Cell and Gene Therapy, Fortrea
Dong Yang, Head of Regulatory, Fortrea China
Dr. Jennifer Hollands, Government and Academic Liaison, Cell Therapies (Subsidiary of Peter MacCallum Cancer Centre)
Eytan Abraham, VP, Business Head of Cell, Gene and Nucleic Acids Franchises, Resilience
Ritu Singla, Project Manager, Fortrea
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2024-05-28
|
|
|
|
|
|
|
|
Registration:
|
|
Free Registration
|
|
|
E-mail:
|
|
tristan@xtalks.com
|
|
|
|
|
|
|
|
|